Definitive Contract 75N92020C00010
Award Date
7/30/20
Potential Completion Date
1/30/22
Potential Value
$17M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Talis Biomedical Corporation
Ultimate Awardee
Talis Biomedical Corp
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) National Institutes of Health National Heart Lung and Blood Institute awarded a $5,253,450.00 firm fixed-price contract to Maxim Biomedical, Inc. to provide RADX TECH SARS-COV-2 antigen rapid tests. The contract has an estimated completion date of August 27, 2023 and was awarded on August 28, 2020. Maxim Biomedical is a small disadvantaged, woman-owned, Asian-Pacific American owned business that specializes in medical device manufacturing,...
This federal contract award, valued at $10,691,445.48, was issued by the National Heart Lung and Blood Institute, a civilian agency within the U.S. government, to the National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell), a non-profit organization. The contract is for Rapid Acceleration of Diagnostics (RADx) Clinical Evaluation Services (CES) - Task Order 9. Venturewell has extensive experience managing federal contracts and grants focused on advancing...
The Department of Health and Human Services National Institutes of Health National Institute of Biomedical Imaging and Bioengineering awarded a $20.7 million firm fixed price definitive contract to Associated Pathologists, LLC (doing business as Pathgroup) for the Rapid Acceleration of Diagnostics (RADX) ATP Program - Project #7338. The contract is being funded under the Coronavirus COVID-19 national interest action code and will support RADX's goal of accelerating the development,...
This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Detect Inc. for the Rapid Acceleration of Diagnostics (RADx) Tech II program. The contract is valued at $8,085,388.00 and has a firm fixed price pricing type. The contract is for the "Expanded Manufacturing and Commercialization of 'Detect' COVID-19 Test: Highly Scalable, Affordable, At-Home Rapid Test" project, with a completion date of October 13, 2022. This contract...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $15 million firm fixed price purchase order to National Collegiate Inventors & Innovators Alliance, Inc., doing business as Venturewell, for the Rapid Acceleration of Diagnostics (RADX) Initiative - Phase 0. As part of the RADX Initiative to accelerate the development, testing, and implementation of novel diagnostics for COVID-19, this contract will support Venturewell's efforts to advance diagnostics through...
This is a $5,240,000.00 firm fixed price definitive contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Lumiradx, Inc., a foreign-owned, for-profit organization. The contract is for Lumiradx to provide a SARS-CoV-2 & Flu A/B high sensitivity antigen assay under the RADX Tech program. The contract has an ultimate completion date of May 31, 2022 and was awarded on September 30, 2021. This contract is not associated with any set-aside designation.
<p>The National Heart, Lung and Blood Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a definitive contract valued at $1,099,350.00 to Rosalind, Inc. for Rapid Acceleration of Diagnostics technology. Rosalind, Inc. will perform all work at its division location in Bethesda, Maryland under firm fixed pricing from December 5, 2022 through December 4, 2023. No subcontractors were identified.</p>
<p>This is a $22,624,000.00 firm fixed price definitive contract awarded by the National Institute of Biomedical Imaging and Bioengineering, a civilian federal agency, to Roche Molecular Systems Inc. for RADX products and services. The contract has a period of performance through May 1, 2024 and does not have a set-aside designation. The award was made on May 2, 2022 and the contractor, Roche Molecular Systems Inc., is a for-profit manufacturer of goods.</p>
This federal contract award was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to the National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell), a non-profit organization based in Hadley, Massachusetts. The $2,097,064.03 firm fixed-price delivery order is for clinical evaluation services in support of the Rapid Acceleration of Diagnostics (RADx) initiative, which aims to...
This is a firm fixed-price federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to Illumina, Inc. The contract, valued at $87,365.00, is for the rapid establishment of a massively scaled next-generation sequencing (NGS) laboratory to support COVID-19 testing in the United States. This contract was awarded under the RAPID ACCELERATION OF DIAGNOSTICS (RADX) program, which aims to speed the development, validation, and...